Cardiovascular Diseases

Skipping Breakfast Linked to Mortality

A US prospective cohort study revealed that skipping breakfast was associated with a significantly increased risk of mortality from cardiovascular disease (CVD). The study included a nationally representative sample of 6,550 adults (mean age 53.2 years; 48.0% male) from 1988 to 1994, with 17 to 23 years of follow-up. In the cohort, 5.1% never consumed breakfast, 10.9% rarely consumed breakfast, 25.0% consumed breakfast some days, and 59.0% consumed breakfast every day. During 112,148 person-years of follow-up, 2,318 deaths occurred including 619 deaths from CVD. After adjustment for age, sex, race/ethnicity, socioeconomic status, dietary and lifestyle factors, body mass index, and CVD risk factors, participants who never consumed breakfast compared with those consuming breakfast everyday had hazard ratios of 1.87 for CVD mortality and 1.19 for all-cause mortality. The findings suggest that a pattern of skipping breakfast identifies a population at risk, either causally linked or just as an epiphenomenon. Source: http://www.onlinejacc.org/

hyangiu

Recent Posts

Global Study of Stroke Risk Factors

A study revealed that stroke remains a major global health challenge, influenced by numerous risk…

1 day ago

Antidepressants Effective and Safe in Older Adults with Anxiety

A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…

2 days ago

Geographical Variation in Lipoprotein (a) Levels Among CHD Patients

A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…

2 weeks ago

The Science and Skepticism around Seed Oils

A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…

3 weeks ago

Bedtime Antihypertensive Comparable to Morning Use

A Canadian study of adults with high blood pressure (BP) found no difference in health…

4 weeks ago

Obicetrapib Effective and Safe in Improving Lipids

Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…

1 month ago

This website uses cookies.